Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019
Viruses · 2024
DOI: 10.3390/v16050718 ↗Kurz gefasst
Fallbericht in der Zeitschrift Viruses, 2024. Verfasst von Chie Yamamoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. Hauptthemen laut MEDLINE: Immunocompromised Host, SARS-CoV-2, Drug Resistance, Viral, Antiviral Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still poses a threat to the immunocompromised and others with underlying diseases. Especially in cases of persistent COVID-19, new mutations conferring resistance to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapies have considerable clinical implications. We present a patient who independently acquired a T21I mutation in the 3CL protease after nirmatrelvir exposure. The T21I mutation in the 3CL protease is one of the most frequent mutations responsible for nirmatrelvir resistance. However, limited reports exist on actual cases of SARS-CoV-2 with T21I and other mutations in the 3CL protease. The patient, a 55 year-old male, had COVID-19 during chemotherapy for multiple myeloma. He was treated with nirmatrelvir early in the course of the disease but relapsed, and SARS-CoV-2 with a T21I mutation in the 3CL protease was detected in nasopharyngeal swab fluid. The patient had temporary respiratory failure but later recovered well. During treatment with remdesivir and dexamethasone, viruses with the T21I mutation in the 3CL protease showed a decreasing trend during disease progression while increasing during improvement. The impact of drug-resistant SARS-CoV-2 on the clinical course, including its severity, remains unknown. Our study is important for examining the clinical impact of nirmatrelvir resistance in COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
- Department of Infectious Disease, Kyoto City Hospital, Kyoto 604-8845, Japan.
- Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
- Department of Infectious Diseases, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
ORCID-Profile: Toru Inaba, Shinsuke Mizutani, Junya Kuroda, Koichi Takayama, Yoko Nukui
Zitieren
APA
Yamamoto, C., Taniguchi, M., Furukawa, K., Inaba, T., Niiyama, Y., Ide, D., Mizutani, S., Kuroda, J., Tanino, Y., Nishioka, K., Watanabe, Y., Takayama, K., Nakaya, T., & Nukui, Y. (2024). Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019. Viruses. https://doi.org/10.3390/v16050718
Vancouver
Yamamoto C, Taniguchi M, Furukawa K, Inaba T, Niiyama Y, Ide D, et al. Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019. Viruses. 2024. doi:10.3390/v16050718
BibTeX
@article{Yamamoto2024,
author = {Yamamoto, Chie and Taniguchi, Masashi and Furukawa, Keitaro and Inaba, Toru and Niiyama, Yui and Ide, Daisuke and Mizutani, Shinsuke and Kuroda, Junya and Tanino, Yoko and Nishioka, Keisuke and Watanabe, Yohei and Takayama, Koichi and Nakaya, Takaaki and Nukui, Yoko},
title = {Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16050718}
}
EUVIMED